Neuroblastoma treatment with taurolidine hydrolysis products
US11541061B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2019 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Aug 28, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.